Sagility’s Chirok Health Acquisition can boost its stock price by 31%, JPMorgan says

The acquisition should add 0.6% and 1% to Sagility’s FY27 and FY28 revenues, respectively, and JPMorgan estimates the transaction to be margin accretive as well.

Leave a Reply

Your email address will not be published. Required fields are marked *